BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LW402 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of LW402\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07556471-1418@assetmemo.bio
DTSTAMP:20261121T004100Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:LW402: Phase 2 readout est. (NCT07556471)
DESCRIPTION:LW402\, phase 2.\nStudy: Evaluation of the Efficacy and Safety 
 of LW402 Tablets in Patients With Non-Segmental Vitiligo\nEstimated primar
 y completion: 1 February 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/lw402#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07556471
URL:https://assetmemo.bio/drug/lw402#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07370909-1418@assetmemo.bio
DTSTAMP:20261121T004100Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:LW402: Phase 3 readout est. (NCT07370909)
DESCRIPTION:LW402\, phase 3\, Atopic Dermatitis.\nStudy: Evaluation of the 
 Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients Wi
 th Moderate-to-Severe Atopic Dermatitis\nEstimated primary completion: 31 
 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lw402#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0737090
 9
URL:https://assetmemo.bio/drug/lw402#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
